Dietary supplementation with L-arginine in patients with breast cancer (&gt; 4 cm) receiving multimodality treatment: report of a feasibility study

Brittenden, Julie; Heys, Steven Darryll; Miller, Iain D.; Sarkar, T. K.; Hutcheon, A. W.; Needham, Gillian; Gilbert, Fiona J.; McKean, M.; Ah‐See, A. K.; Eremin, O.

doi:10.1038/bjc.1994.177

Cited by 23 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, L-arginine can be classified as a semi-essential amino acid, where endogenous synthesis may be insufficient as in situations of accelerated tissue growth after infection (61). Progressive loss of kidney function, hypertension, and hypertensive nephrosclerosis occurs in a Dahl/Rapp salt-sensitive rat model and can be reversed following L-arginine treatment through a mechanism that likely involves NO ⅐ -mediated vascular smooth muscle cell relaxation and subsequent decreased blood pressure (62). LArginine may also enhance the immune response in patients with breast cancer by enhancing the mitogenic responses of peripheral blood lymphocytes (63).…”

Section: Discussionmentioning

confidence: 99%

Nitric Oxide Inhibition of ERK1/2 Activity in Cells Expressing Neuronal Nitric-oxide Synthase

Raines

Cao

Porsuphatana

et al. 2004

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Nitric Oxide Inhibition of ERK1/2 Activity in Cells Expressing Neuronal Nitric-oxide Synthase

Raines

Cao

Porsuphatana

et al. 2004

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Histological responses of excised breast tissue were assessed by one consultant breast histopathologist (IM) as previously documented (Brittenden et al, 1994). Briefly, the response to chemotherapy is graded according to the residual tumour found histologically as follows: type I -changes in tumour cells but tumour nests not destroyed; type II -tumour structure destroyed to a minor degree; type III -tumour structure destroyed to a moderate degree; type IV -tumour structure destroyed to a severe degree; type V -no tumour cells in any of the specimens.…”

Section: Assessment Of Clinical and Pathological Response To Chemothementioning

confidence: 99%

Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy

et al. 1999

Self Cite

View full text Add to dashboard Cite

SummaryThe diagnosis and treatment of breast cancer are stressful, and stress may be associated with a poorer response to chemotherapy. There is a need, therefore, to develop and evaluate interventions that might enhance quality of life and, possibly, improve treatment response. The effects of relaxation combined with guided imagery (visualizing host defences destroying tumour cells) on quality of life and response to primary chemotherapy, to date, have not been adequately evaluated. Ninety-six women with newly diagnosed large or locally advanced breast cancer (T 2 > 4 cm, T 3 , T 4 , or T x N 2 and M 0 ) took part in a prospective, randomized controlled trial. Patients were randomized following diagnosis to a control condition (standard care) or to the experimental condition (standard care plus relaxation training and imagery). Psychometric tests to evaluate mood and quality of life were carried out before each of the six cycles of chemotherapy and 3 weeks after cycle 6: tests of personality and coping strategy were carried out prior to cycles one and six. Clinical response to chemotherapy was evaluated after six cycles of chemotherapy using standard UICC criteria and pathological response was assessed from the tissue removed at surgery. As hypothesized, patients in the experimental group were more relaxed and easy going during the study (Mood Rating Scale). Quality of life was better in the experimental group (Global Self-assessment and Rotterdam Symptom Checklist). The intervention also reduced emotional suppression (Courtauld Emotional Control Scale). The incidence of clinically significant mood disturbance was very low and the incidence in the two groups was similar. Finally, although the groups did not differ for clinical or pathological response to chemotherapy, imagery ratings were correlated with clinical response. These simple, inexpensive and beneficial interventions should be offered to patients wishing to improve quality of life during primary chemotherapy.

show abstract

“…This proved that L-arginine didn't affect the anticancer activity of PDD. L-arginine also have anticancer activity by many mechanisms: (1) Facilitate body's immunity [12] ; (2) Inhibit cancer cell directly [13] ; (3) Increase the effect of chemotherapy [14] .…”

Section: Discussionmentioning

confidence: 99%

Dosage of L-arginine Preventing Acute High-dose PDD Nephrotoxicity

Wang

Liu

2005

Chinese-German J Clin Oncol

View full text Add to dashboard Cite

Objective: To explore the optimal dose of L-arginine to prevent acute high-dose (HD)-PDD nephrotoxicity. Methods: 128 cases using PDD with the dosage of 100 mg/m 2 within two days (D1, 2) in combination with L-arginine were randomly divided into 3 groups of A, B and C. The dosages of Larginine in the 3 groups were 5 g/(m 2 ·d), 10 g/(m 2 ·d) and 15 g/(m 2 ·d), respectively. Each patient received 2 cycles chemotherapy to form self control: 1 cycle combined with L-arginine, while 1 cycle chemotherapy alone. β2-MG in urine, BUN, Cr and uric acid in blood were detected just 24 h before and after using PDD. The changes of each index in the three groups were observed in the presence or absence, and the therapeutic effects were compared among the three groups. Results: There was no significant difference in BUN, Cr and uric acid in blood before and after chemotherapy in the presence or absence, showing these indexes could not be used as markers of early acute nephrotoxicity. Urine β2-MG values in the presence and absence were 0.9120±0.6618 vs 1.5167±0.7908 (P <0.05), 0.5404±0.5810 vs 1.4616±0.8120 (P <0.01), 0.4998±0.6210 vs 1.5210±0.7710 (P <0.01) in the groups A, B and C respectively. The excellent effective rate and total effective rate in groups A, B and C were 40.9% and 59.1%, 68.2% and 90.9%, and 77.5% and 97.5%, respectively. There was significant difference in the excellent effective rate and total effective rate between groups A and B, but not between groups B and C. Conclusion: The optimal dose of Larginine to prevent acute HD-PDD nephrotoxicity is 10 g/(m 2 ·d). Increased dosage can't improve the effect accordingly.

show abstract

Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study

Cited by 23 publications

References 15 publications

Nitric Oxide Inhibition of ERK1/2 Activity in Cells Expressing Neuronal Nitric-oxide Synthase

Nitric Oxide Inhibition of ERK1/2 Activity in Cells Expressing Neuronal Nitric-oxide Synthase

Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy

Dosage of L-arginine Preventing Acute High-dose PDD Nephrotoxicity

Contact Info

Product

Resources

About